Suppr超能文献

恶性腹膜间皮瘤:综述

Malignant peritoneal mesothelioma: a review.

作者信息

Kim Joseph, Bhagwandin Shanel, Labow Daniel M

机构信息

Division of Surgical Oncology, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Ann Transl Med. 2017 Jun;5(11):236. doi: 10.21037/atm.2017.03.96.

Abstract

Mesothelioma is a malignancy of serosal membranes. It is most commonly encountered in the visceral pleura with the second most common location in the peritoneum. The diagnosis is very rare and has been linked to toxic exposure to industrial pollutants, especially asbestos. Malignant peritoneal mesothelioma (MPM) commonly presents with diffuse, extensive spread throughout the abdomen with rare metastatic spread beyond the abdominal cavity. Due to its rarity and nonspecific symptoms, it is usually diagnosed late when the disease burden is extensive. Because pleural mesothelioma is more common than MPM, most research has been on the pleural variant and extrapolated for MPM. While treatment advances have been made for MPM, the disease is universally fatal from either abdominal complications secondary to the spread of disease or starvation. Untreated, the life expectancy is less than a year. Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) has become the mainstay of therapy with systemic therapies still being developed. We will review the epidemiology of MPM and discuss diagnostic and treatment strategies.

摘要

间皮瘤是一种浆膜恶性肿瘤。它最常见于脏层胸膜,其次常见于腹膜。这种诊断非常罕见,并且与工业污染物尤其是石棉的有毒暴露有关。恶性腹膜间皮瘤(MPM)通常表现为在整个腹部弥漫性、广泛性扩散,很少有超出腹腔的转移扩散。由于其罕见性和非特异性症状,通常在疾病负担广泛时才被诊断出来。因为胸膜间皮瘤比MPM更常见,大多数研究都集中在胸膜型,并外推用于MPM。虽然MPM的治疗取得了进展,但该疾病通常因疾病扩散引起的腹部并发症或饥饿而致命。未经治疗,预期寿命不到一年。细胞减灭术(CRS)联合热灌注化疗(HIPEC)已成为主要治疗方法,全身治疗仍在研发中。我们将回顾MPM的流行病学,并讨论诊断和治疗策略。

相似文献

1
Malignant peritoneal mesothelioma: a review.
Ann Transl Med. 2017 Jun;5(11):236. doi: 10.21037/atm.2017.03.96.
3
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Front Oncol. 2021 Jun 18;11:704295. doi: 10.3389/fonc.2021.704295. eCollection 2021.
4
Malignant peritoneal mesothelioma: a review.
Transl Lung Cancer Res. 2018 Oct;7(5):537-542. doi: 10.21037/tlcr.2018.10.04.
5
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.
Ann Gastroenterol. 2018 Nov-Dec;31(6):659-669. doi: 10.20524/aog.2018.0305. Epub 2018 Sep 14.
6
Malignant peritoneal mesothelioma literature review: past, present, and future.
Dig Med Res. 2022 Jun;5. doi: 10.21037/dmr-22-19. Epub 2022 Jun 30.
7
Treatment of Malignant Peritoneal Mesothelioma.
Klin Onkol. 2019 Fall;32(5):333-337. doi: 10.14735/amko2019333.
8
Malignant Peritoneal Mesothelioma: A Case Report.
Cureus. 2023 Aug 3;15(8):e42902. doi: 10.7759/cureus.42902. eCollection 2023 Aug.
9
Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
Int J Surg Protoc. 2023 Sep 26;27(3):108-117. doi: 10.1097/SP9.0000000000000010. eCollection 2023 Dec.
10
Diagnosis and management of patients with malignant peritoneal mesothelioma.
J Gastrointest Oncol. 2016 Feb;7(1):79-86. doi: 10.3978/j.issn.2078-6891.2015.134.

引用本文的文献

1
A rare presentation of peritoneal mesothelioma: Esophageal encasement and Sister Mary Joseph nodule.
Radiol Case Rep. 2025 Aug 7;20(11):5407-5410. doi: 10.1016/j.radcr.2025.07.033. eCollection 2025 Nov.
2
Long Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis.
Cureus. 2025 Jun 13;17(6):e85973. doi: 10.7759/cureus.85973. eCollection 2025 Jun.
3
Consensus Guideline for the Management of Peritoneal Mesothelioma.
Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17358-x.
4
Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study.
Am J Case Rep. 2025 Apr 10;26:e946585. doi: 10.12659/AJCR.946585.
5
A woman with a pleural mesothelioma and an inherited mutation-a case report.
Ann Transl Med. 2025 Feb 28;13(1):8. doi: 10.21037/atm-24-138. Epub 2025 Feb 25.
6
Development and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma.
Front Oncol. 2025 Feb 28;15:1480197. doi: 10.3389/fonc.2025.1480197. eCollection 2025.
9
Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions.
BJC Rep. 2024 May 24;2(1):42. doi: 10.1038/s44276-024-00062-w.

本文引用的文献

2
Global mesothelioma epidemic: Trend and features.
Indian J Occup Environ Med. 2014 May;18(2):82-8. doi: 10.4103/0019-5278.146897.
4
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
PLoS One. 2014 Sep 15;9(9):e105919. doi: 10.1371/journal.pone.0105919. eCollection 2014.
9
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Ann Surg Oncol. 2014 Apr;21(4):1159-65. doi: 10.1245/s10434-013-3358-y. Epub 2013 Dec 10.
10
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验